(2 intermediate revisions by the same user not shown) | |||
Line 77: | Line 77: | ||
<a class="nav-link" href="https://2018.igem.org/Team:Edinburgh_UG/Safety">Safety <span class="sr-only">(current)</span></a> | <a class="nav-link" href="https://2018.igem.org/Team:Edinburgh_UG/Safety">Safety <span class="sr-only">(current)</span></a> | ||
</li> | </li> | ||
− | <li class="nav-item | + | <li class="nav-item active"> |
− | <a class="nav-link | + | <a class="nav-link" href="https://2018.igem.org/Team:Edinburgh_UG/Human_Practices">Human Practices <span class="sr-only">(current)</span></a> |
− | + | </li> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | </li> | + | |
<li class="nav-item dropdown"> | <li class="nav-item dropdown"> | ||
<a class="nav-link dropdown-toggle" href="#" id="navbarDropdownMenuLink" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> | <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownMenuLink" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> | ||
Line 111: | Line 106: | ||
<div class="row"> | <div class="row"> | ||
<div class="col-lg-8 mx-auto"> | <div class="col-lg-8 mx-auto"> | ||
− | <h1 class="brand-heading">Improve</h1> | + | <h1 class="brand-heading" align="center">Improve</h1> |
<p class="intro-text"></p> | <p class="intro-text"></p> | ||
</div> | </div> | ||
Line 156: | Line 151: | ||
<div class="col-lg-8 mx-auto"> | <div class="col-lg-8 mx-auto"> | ||
<h2 style="text-align:left">BBa_K2725012 & BBa_K2725013</h2> | <h2 style="text-align:left">BBa_K2725012 & BBa_K2725013</h2> | ||
− | <p style="text-align:left">We improved the previous parts: BBa_K914009 & BBa_K914018, which contain a kanamycin | + | <p style="text-align:left">We improved the previous parts: <a href="http://parts.igem.org/Part:BBa_K914009">BBa_K914009</a> & <a href="http://parts.igem.org/Part:BBa_K914018">BBa_K914018</a>, which contain a kanamycin |
resistance gene with one and two serine -> amber codon mutations, respectively. By | resistance gene with one and two serine -> amber codon mutations, respectively. By | ||
− | increasing the number of serine -> amber codon mutations to 5 in BBa_K2725012 and to 10 | + | increasing the number of serine -> amber codon mutations to 5 in <a href="http://parts.igem.org/Part:BBa_K2725012">BBa_K2725012</a> and to 10 |
− | in BBa_K2725013, they confer a decreased kanamycin resistance in the absence of a | + | in <a href="http://parts.igem.org/Part:BBa_K2725013">BBa_K2725013</a>, they confer a decreased kanamycin resistance in the absence of a |
− | suppressor tRNA, reducing the leakiness of the gene.</p> | + | suppressor tRNA, reducing the leakiness of the gene and thereby increasing its safety.</p> |
</div> | </div> | ||
</div> | </div> |
Latest revision as of 01:30, 18 October 2018
Improve
BBa_K2725001
We improved the characterisation of a previous part: BBa_K771303, which contains the coding sequence of E. coli FabI. FabI is involved in type 2 fatty acid synthesis and has previously been characterised as a biosensor for triclosan, a common biocide. Overexpression of FabI has been shown to give resistance to triclosan, so we characterised the use of FabI as an alternative selection gene. Usage of triclosan instead of antibiotics is considerably cheaper, and safer for the environment.
BBa_K914009 & BBa_K914018
We improved the characterisation of the previous parts: BBa_K914009 & BBa_K914018, which contain a kanamycin resistance gene with one and two serine -> amber codon mutations, respectively. Previously, their kanamycin resistance with and without a suppressor tRNA were characterised in E. coli MG1655. We further characterised their ability to confer resistance in E. coli TOP10 and made further parts with a larger number of amber mutations.
BBa_K2725012 & BBa_K2725013
We improved the previous parts: BBa_K914009 & BBa_K914018, which contain a kanamycin resistance gene with one and two serine -> amber codon mutations, respectively. By increasing the number of serine -> amber codon mutations to 5 in BBa_K2725012 and to 10 in BBa_K2725013, they confer a decreased kanamycin resistance in the absence of a suppressor tRNA, reducing the leakiness of the gene and thereby increasing its safety.
Contact EdiGEM18
Feel free to leave us a comment on social media!